Radiopharmaceutical approval timeline
Regulatory approvals of therapeutic and diagnostic radiopharmaceuticals, newest first; every row links to its source.
United States (FDA)
- 31 July 2026
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Therapy
Indication expansion: with ARPI therapy, PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S; formerly hormone-sensitive) prostate cancer (PSMAddition); patients selected with Locametz or another approved PSMA PET agent
- 28 March 2025
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Therapy
Indication expansion: PSMA-positive mCRPC after ARPI in patients appropriate to delay taxane chemotherapy (PSMAfore)
- 20 March 2025
Gozellix (kit for Ga 68 gozetotide) Diagnostic
PSMA PET in prostate cancer (kit with a longer shelf life)
- 27 September 2024
Flyrcado (flurpiridaz F 18) Diagnostic
PET myocardial perfusion imaging in known or suspected coronary artery disease
- 23 April 2024
Lutathera (lutetium Lu 177 dotatate) Therapy
SSTR-positive GEP-NETs in children aged 12 and older (first paediatric radiopharmaceutical therapy approval)
- 25 May 2023
- 23 March 2022
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Therapy
PSMA-positive mCRPC after androgen receptor pathway inhibition and taxane chemotherapy
- 23 March 2022
Locametz (kit for Ga 68 gozetotide) Diagnostic
PSMA PET; the first diagnostic agent approved for selecting patients for Lu-177 PSMA therapy
- 17 December 2021
- 27 May 2021
Pylarify (piflufolastat F 18) Diagnostic
PSMA PET in prostate cancer (suspected metastasis or PSA-based suspected recurrence)
- 1 December 2020
Ga 68 PSMA-11 (UCLA, UCSF) (gallium Ga 68 PSMA-11) Diagnostic
PET of PSMA-positive lesions in prostate cancer (first PSMA PET approval)
- 3 September 2020
Detectnet (copper Cu 64 dotatate) Diagnostic
PET localisation of SSTR-positive neuroendocrine tumours
- 28 May 2020
Tauvid (flortaucipir F 18) Diagnostic
PET estimate of tau neurofibrillary tangles in adults with cognitive impairment evaluated for Alzheimer's disease
- 20 May 2020
Cerianna (fluoroestradiol F 18) Diagnostic
PET detection of oestrogen receptor-positive lesions in recurrent or metastatic breast cancer (adjunct to biopsy)
- 21 August 2019
Ga 68 DOTATOC (gallium Ga 68 dotatoc) Diagnostic
PET localisation of SSTR-positive neuroendocrine tumours
- 26 January 2018
Lutathera (lutetium Lu 177 dotatate) Therapy
SSTR-positive gastroenteropancreatic neuroendocrine tumours in adults
- 1 June 2016
Netspot (kit for Ga 68 dotatate) Diagnostic
PET localisation of SSTR-positive neuroendocrine tumours
- 27 May 2016
Axumin (fluciclovine F 18) Diagnostic
PET in men with suspected prostate cancer recurrence based on elevated PSA after prior treatment
- 15 May 2013
Xofigo (radium Ra 223 dichloride) Therapy
Castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases
European Union (EMA, first EU authorisation)
- 9 December 2022
Pluvicto (lutetium (177Lu) vipivotide tetraxetan) Therapy
Progressive PSMA-positive mCRPC after ARPI and taxane chemotherapy (first EU authorisation)
- 9 December 2022
Locametz (gozetotide (kit for Ga 68)) Diagnostic
PSMA PET in prostate cancer, including selection of patients for PSMA-targeted therapy
- 26 September 2017
Lutathera (lutetium (177Lu) oxodotreotide) Therapy
Unresectable or metastatic, progressive, well-differentiated SSTR-positive GEP-NETs in adults
- 22 May 2017
Axumin (fluciclovine (18F)) Diagnostic
PET in suspected prostate cancer recurrence after primary treatment
- 8 December 2016
SomaKit TOC (edotreotide (kit for Ga 68)) Diagnostic
PET localisation of well-differentiated gastroenteropancreatic neuroendocrine tumours
- 13 November 2013
Xofigo (radium Ra 223 dichloride) Therapy
Castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases (first EU authorisation)
Türkiye (TİTCK)
- 24 October 2025
Tektrotyd (HYNIC-[D-Phe1,Tyr3]-oktreotid) Diagnostic
Somatostatin analogue kit labelled with Tc-99m for SSTR scintigraphy (licence no 2025/473)
- 9 February 2023
MON.FDOPA (18F) ([18F] florodopa) Diagnostic
F-18 FDOPA PET agent (licence no 2023/28)
- 29 November 2022
GalliaPharm (germanyum-68/galyum-68 jeneratörü) Diagnostic
Ge-68/Ga-68 radionuclide generator for preparing Ga-68-labelled kits (licence no 2022/687)
- 14 October 2021
Ankükolin (18F) ([18F] florokolin) Diagnostic
F-18 fluorocholine PET agent (licence no 2021/378)
- 19 December 2019
MON.LUTEC (lutesyum (177Lu) klorür) Therapy
Lu-177 radiopharmaceutical precursor for radiolabelling, not for direct administration (licence no 2019/703)
- 10 October 2019
Vizamyl ((18F) flutemetamol) Diagnostic
Amyloid PET agent (licence no 2019/515)
- 6 June 2016
Xofigo (radyum-223 diklorür) Therapy
Ra-223 dichloride solution for injection (licence no 2016/473)
Sources: FDA approval letters and Drugs@FDA; for the EU, the European Commission Union Register decision granting the first authorisation; for Türkiye, the TİTCK list of licensed human medicinal products (13 November 2026). EU rows show the first authorisation only, not later indication extensions. Lutathera, Pluvicto and Locametz are not on the TİTCK list as of that date. Licensing differs by country; this list is not treatment advice.